Indication: Myelodysplastic Syndromes (MDS), Colorecral Cancer (CRC) and Prostate Cancer (PrC)
Title: Study of the Safety, Tolerability and Efficacy of KPT-8602 in Patients With Relapsed/Refractory Cancer Indications
Drug: eltanexor

Rights

Drug: eltanexor. Combination study expected to start in 2020.

Phase IPhase IIPhase III
Phase I
Phase II
Phase III